Research
Hormonal
Multi-receptor agonists (tirzepatide, retatrutide) and oral GLP-1 receptor agonists (orforglipron) are emerging treatments that reduce body weight and improve metabolic health.
Newer multi-receptor agonists (tirzepatide, retatrutide) and oral GLP-1 agonists (orforglipron) are in clinical trials or recently approved, offering once-weekly or daily options to reduce body weight and improve cardiac metabolism in adults with obesity.
GoodSupportsHIGH confidence
Tirzepatide is the agonist of GLP-1 receptor and glucose-dependent insulinotropic polypeptide (GIP) receptor, which can reduce body weight and improve cardiac metabolism by subcutaneous injection once a week... Retatrutide is the agonist of GLP-1 receptor, GIP receptor, and glucagon (GCG) receptor, which can reduce body weight and improve blood glucose by subcutaneous injection once a week... oral micromolecular GLP-1 receptor agonists such as orforglipron have already in clinical trials, which can reduce body weight and improve cardiac metabolism in adults with obesity
Why this rating
Cites phase 2 trials and clinical trials, but some are still in development.
Source
The transformative breakthroughs in GLP-1 research recognized by the 2024 Lasker~DeBakey award
Yu-Fei Zhou et al. · Current Medicine · 2024
DOI 10.1007/s44194-024-00041-w
narrative_review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- GLP-1 receptor agonists (e.g., liraglutide, semaglutide) induce significant weight loss in individuals with obesity by suppressing appetite and reducing energy intake through central nervous system mechanisms.Strong
- GLP-1 receptor agonists (liraglutide, semaglutide) mitigate cardiovascular risks and may reduce atherosclerosis through anti-inflammatory mechanisms.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →